ELI LILLY AND COMPANY |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 782.6 USD | +2.61% |
|
+0.80% | +34.01% |
| 04:49pm | UK weight-loss drug price rivalry intensifies with Pharmacy2U mark-down | RE |
| 02:43pm | Eli Lilly Ethics/Compliance Chief Alonzo Weems to Retire | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
764
USD
Average target price
850.4
USD
Spread / Average Target
+11.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +34.01% | 688B | |
| +31.37% | 588B | |
| -2.79% | 364B | |
| +20.41% | 326B | |
| +5.49% | 285B | |
| +14.83% | 239B | |
| +9.93% | 210B | |
| -6.95% | 200B | |
| +11.17% | 167B | |
| +0.13% | 161B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Truist Raises Price Target on Eli Lilly to $892 From $850, Keeps Buy Rating
